SCHEMBL8429670

SCHEMBL8429670

CCC(=CN(C)C(=O)OC(C)(C)C)c1ccc(NC(C)=O)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.36
CYP1A2 P05177 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
P4HTM Q9NXG6 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
MAPT P10636 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPR3 P17342 4/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
ADORA2A P29274 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8429241 0.80 AAK1 (0.38) SMN1; SMN2L3MBTL1AAK1
SCHEMBL8427659 0.75 KMT2A (0.42) CYP1A2MEN1LMNAKMT2ATDP1
SCHEMBL6664110 0.70 FPR3 (0.37) TRPV1CYP1A2MEN1LMNAKMT2A
SCHEMBL2012546 0.67 NAMPT (0.50) P4HTM
SCHEMBL31661246 0.67 ALDH1A1 (0.50) CYP1A2MEN1LMNAKMT2ATDP1
SCHEMBL20934803 0.66 NAMPT (0.47) P4HTMADORA2A
SCHEMBL19470129 0.66 NAMPT (0.49) ADORA2A
SCHEMBL31598929 0.66 MAPK1 (0.59) CYP1A2MEN1LMNAKMT2ATDP1
SCHEMBL3621493 0.65 P4HTM (0.63) KMT2AP4HTMSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL8781612 0.65 HPGD (0.53) CYP1A2MEN1LMNAKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5861423-A SIDE EFFECT REDUCTION; ADMINISTERING TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; ATTENTION DEFICIT DISORDER, SCHIZOPHRENIA TARGACEPT, INC., A CORPORATION OF DELAWARE 1999-01-19 US disclosed
US-5811442-A ADMINISTERING ARYL SUBSTITUTED OLEFINIC AMINE COMPOUND IN AN AMOUNT SUFFICIENT TO SELECTIVELY BIND TO AND AFFECT NICOTINIC CHOLINERGIC RECEPTOR SUBTYPES CONTAINING BETA2 SUBUNITS TARGACEPT, INC. 1998-09-22 US disclosed